Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Denmark / NCT04331522
Recruiting Observational

Allergen Provocations- HCA Children's Hospital

NCT04331522 · tracked via the Priya Life Science Denmark tracker
Sponsor
Josefine Gradman
Phase
Observational
Started
2018-10-01
Last updated
2025-07-10

Condition(s) studied

Allergy in Children

Investigational drug(s) / intervention(s)

Oral provocation test

Oral provocation test: Titrated provocation with allergen

Study summary

A prospective study of all allergen provocations performed in children at the Hans Christian Andersen Children's Hospital.

Eligibility

Sex
ALL
Min age
0 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: clinical suspicion of allergy to foods or antibiotics informed concent - Exclusion Criteria: \-

Primary outcome measure(s)

  • The association of allergy tests with the result of allergen provocation — 5 years
    The value of specific IgE and SPT to predict the outcome of a allergen provocation

Trial sites (1)

FacilityCityRegionStatus
Hans Christian Andersen Children's Hospital Odense Odense C Recruiting

Other trials for the same condition

Long Term Effect of AIT in Children Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04331522 on ClinicalTrials.gov ↗ ← All trials in Denmark